Could a common seizure drug plus a supplement curb alcoholism?

NCT ID NCT03120468

Completed Disease control Sponsor: Nassima Ait-Daoud Tiouririne Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase pilot study tested whether combining topiramate (a seizure medication) with N-acetyl cysteine (a supplement) is safe and tolerable for people with alcohol use disorder. Seventeen adults who were heavy drinkers and seeking treatment took either the combination or topiramate alone for 12 weeks. The study focused on side effects and drinking patterns, but it was too small to draw firm conclusions about effectiveness.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Topiramate and N-acetyl cysteine
What this could lead to: If it works, this could point toward a new combination treatment to help people reduce heavy drinking.
What could go wrong: This is a very early, small pilot study with only 17 participants. The main goal is safety, not effectiveness, so results may not lead to a proven treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALCOHOL USE DISORDER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alcohol abuse Behavior, Addictive

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALCOHOLISM

Contacts and locations

Locations

UVA Center for Leading Edge Addiction Research

Charlottesville, Virginia, 22903, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.